Literature DB >> 19924586

Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.

P Zwanzger1, D Eser, C Nothdurfter, T C Baghai, H-J Möller, F Padberg, R Rupprecht.   

Abstract

INTRODUCTION: There is evidence that a decreased GABAergic tone plays a role in the pathophysiology of panic disorder (PD). Selective GABAergic treatment has been suggested as a new therapeutic strategy in PD. In this pilot-study anxiolytic effects of the GABA reuptake inhibitor tiagabine (TGB) were investigated in PD.
METHODS: A total of 19 patients were treated with TGB (n=10) or placebo (n=9) for 4 weeks. PAS, HAM-A, and CGI ratings were administered every week. To further assess specific antipanic activity, panic challenges with CCK-4 were carried out in single subjects.
RESULTS: Although there was a significant reduction of clinical rating scores over time, no differences were detected between the groups. However, during challenge experiments TGB treated subjects showed decreased sensitivity to CCK-4. DISCUSSION: Whereas tiagabine did not show beneficial effects on clinical symptoms in PD compared to placebo, results of challenge experiments suggest effects of TGB on sensitivity to experimentally induced panic. Copyright Georg Thieme Verlag KG Stuttgart New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924586     DOI: 10.1055/s-0029-1241798

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

Review 1.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

Review 2.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 3.  Neuroimaging in anxiety disorders.

Authors:  Kathrin Holzschneider; Christoph Mulert
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 4.  Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 5.  Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review.

Authors:  Vasilios G Masdrakis; David S Baldwin
Journal:  Ther Adv Psychopharmacol       Date:  2021-03-21

Review 6.  Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.

Authors:  Madeeha Nasir; Daniel Trujillo; Jessica Levine; Jennifer B Dwyer; Zachary W Rupp; Michael H Bloch
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

Review 7.  GABAergic System in Stress: Implications of GABAergic Neuron Subpopulations and the Gut-Vagus-Brain Pathway.

Authors:  Xueqin Hou; Cuiping Rong; Fugang Wang; Xiaoqian Liu; Yi Sun; Han-Ting Zhang
Journal:  Neural Plast       Date:  2020-08-01       Impact factor: 3.599

Review 8.  KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.